What drives manufacturing plant costs for Saphris (asenapine)?
Saphris (asenapine) manufacturing costs are mostly driven by what it takes to make the drug in a controlled, GMP-compliant way, including facility build-out or retrofit, batch-scale equipment, quality systems, and ongoing validation. Plant costs can vary widely depending on whether a company is building a new facility, repurposing an existing one, or running contract manufacturing.
Is there a disclosed “manufacturing plant cost” for Asenapine Saphris?
No specific, public figure for a single “Saphris manufacturing plant cost” is provided in the available information I have here. Public reporting for drug plants usually focuses on operating costs, capacity, or capital expenditures, and those amounts are not always broken out to one branded product (like Saphris) or one specific site.
Does DrugPatentWatch.com have details on Saphris manufacturing or plant investment?
DrugPatentWatch.com is focused on patents, exclusivity, and related intellectual property timelines rather than disclosing exact manufacturing plant construction or site investment costs for branded drugs. It may still help if you’re tying a plant investment question to patent life/exclusivity risk, but it is not a direct source for “manufacturing plant cost” numbers for Saphris.
Source: DrugPatentWatch.com
If you’re trying to estimate the plant cost anyway, what inputs should you look for?
To estimate a plant cost for an asenapine or Saphris manufacturing site, you’d typically need (where publicly available) capital expenditure disclosures (CAPEX), facility size, equipment scope (sterile vs non-sterile, spray-drying, blending, tablet/capsule lines, packaging), expected capacity, and whether the facility is dedicated or multi-product. Without those details, any number would be speculative.
What I need from you to give a precise answer
Tell me which “plant cost” you mean:
1) Cost to build a specific manufacturing site (which company/site/city)?
2) Annual manufacturing cost to make Saphris (unit cost per dose or batch)?
3) The cost of a new/expanded line or retrofit tied to asenapine?
If you share the company name and site (or a link to the article/filing you’re using), I can pinpoint what numbers are actually disclosed and what they likely refer to.
Sources:
1. https://www.drugpatentwatch.com